Connect with us

IVI, INOVIO, and KNIH partner with CEPI in a Phase I/II trial of INOVIO’s COVID-19 vaccine

IVI, INOVIO, and KNIH partner with CEPI in a Phase I/II trial of INOVIO’s COVID-19 vaccine

Published

on

The Coalition for Epidemic Preparedness Innovations (CEPI) grants funding $6.9 million to INOVIO and IVI to conduct clinical testing in Korea for INOVIO’s COVID-19 vaccine candidate based on their well-established DNA platform technology

IMAGE

Credit: IVI

  • The Coalition for Epidemic Preparedness Innovations (CEPI) grants funding $6.9 million to INOVIO and IVI to conduct clinical testing in Korea for INOVIO’s COVID-19 vaccine candidate based on their well-established DNA platform technology
  • Korea National Institute of Health (KNIH) to support IVI’s testing efforts

April 16, 2020, SEOUL, Korea and Plymouth Meeting, Pa. USA – The International Vaccine (IVI) announced today that the Coalition for Epidemic Preparedness Innovations (CEPI) has granted $6.9 million funding to INOVIO (NASDAQ:INO) to work with IVI and the Korea National Institute of Health (KNIH) for Phase I/II clinical trial of INOVIO’s COVID-19 vaccine candidate (INO-4800) in South Korea. IVI will conduct the trial in parallel to INOVIO’s Phase I INO-4800 study currently underway in the US since April 6, 2020 with 40 healthy adults receiving the vaccine candidate and eventually expanding to older adults.

Dr. Jerome H. Kim, Director General of IVI, said, “Vaccines are the long-term solution to controlling the COVID-19 pandemic. The rapid global response to developing vaccine candidates has been a profound demonstration of governments, industry, and the scientific community coming together to confront a common crisis, and we’re looking forward to accelerating one of those candidates through clinical testing. IVI has achieved promising trial results with INOVIO’s DNA vaccine platform in the past, and we’re pleased to partner again to test the safety and immunogenicity of an urgently needed COVID-19 vaccine.”

Dr. J. Joseph Kim, INOVIO’s President and CEO, said, “Developing a safe and effective COVID-19 vaccine is a global imperative, and we’re pleased to partner with IVI and KNIH to test INO-4800 in South Korea. Our DNA vaccine platform was one of the first technologies to receive support from CEPI to accelerate a COVID-19 vaccine, and IVI conducting safety and efficacy trials in South Korea is a crucial step forward in evaluating this vaccine.”

Dr. Richard Hatchett, CEO of CEPI said, “Developing a safe and effective vaccine and ensuring its global supply is our best exit strategy from the COVID-19 pandemic. CEPI is pleased to work with Inovio and IVI in this critical next stage of testing.”

INOVIO’s DNA vaccine platform is also utilized in their MERS vaccine, INO-4700, for which IVI previously conducted Phase I clinical testing with GeneOne Life Science in South Korea.

This news follows the announcement from the Korean Ministry of Food and Drug Safety made on April 13th that they will adopt a fast-track approval process for COVID-19 vaccine and treatment clinical trials. The period of clinical trial screening will be shortened to seven days (down from 30 days) for substances with experience in use and within 15 days for new materials. Additionally, vaccines developed with a proven safety platform, such as INOVIO’s DNA platform, will be exempt from toxicology tests which will minimize data submission and expedite clinical trials. Plumbline Life Sciences (XKRX: 222670) of South Korea will also collaborate on this project. Korea Centers for Disease Control and Prevention (KCDC) and the KNIH have also pledged their support for IVI’s testing efforts.

###

About the International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). Headquartered in Seoul, South Korea, IVI was the first international organization hosted by Korea. IVI has 35 signatory countries and the World Health Organization (WHO) on its treaty, including Republic of Korea, Sweden and India as state funders.

Our mandate is to make vaccines available and accessible for the world’s most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, Group A Streptococcus, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit https://www.ivi.int

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO’s lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/DOD, GeneOne Life Science/VGXI, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards “W” designation recognizing companies with more than 20% women on their board of directors. For more information, visit http://www.inovio.com.

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil society organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated 8 partnerships to develop vaccines against the novel coronavirus. The programmes will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.

Before the emergence of COVID-19 CEPI’s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).

CONTACT

IVI Media:
Youngmi Cho, Head of Global Affairs & Communications, +82-2-881-1439, youngmi.cho@ivi.int

Aerie Em, Global Communications & Media Specialist, +82-2-881-1386, aerie.em@ivi.int

INOVIO Media:
Jeff Richardson, VP of Communications & Strategic Relations, +1-267-440-4211, jrichardson@inovio.com

CEPI:
Rachel Grant, Director of Communications and Advocacy, Rachel.Grant@cepi.net

Media Contact
Youngmi Cho
youngmi.cho@ivi.int

Original Source

https://www.ivi.int/ivi-inovio-and-knih-to-partner-with-cepi-in-a-phase-i-ii-clinical-trial-of-inovios-covid-19-dna-vaccine-in-south-korea/

Read More

Continue Reading

International

TikTok Ban Obscures Chinese Stock Gold Rush

No one wants to invest in China right now. The country’s stock market is teetering on the brink of collapse. And it is about to lose its biggest foothold…

Published

on

No one wants to invest in China right now.

The country’s stock market is teetering on the brink of collapse.

And it is about to lose its biggest foothold in America — TikTok.

Yet, beneath its crumbling economy, military weather balloons and blatant propaganda tools lie some epic opportunities…

…if you have the stomach and the knowledge.

Because as Jim Woods wrote in his newsletter last month:

“China has been so battered for so long, that there is a lot of deep value here for the ‘blood in the ‘’red’’ streets’ investors.”

And boy was he right.

However, this battle-tested veteran didn’t recommend buying individual Chinese stocks.

He was more interested in the exchange-traded funds (ETFs) like the CHIQ.

And here’s why…

Predictable Manipulation

China’s heavy-handed approach creates gaping economic inefficiencies.

When markets falter, President Xi calls on his “national team” to prop up prices.

$17 billion flowed into index-tracking funds in January as the Hang Sang fell over 13% while the CSI dropped over 7%.

Jim Woods saw this coming from a mile away.

In late February, he highlighted the Chinese ETF CHIQ in late February, which has rallied rather nicely since then.

This ETF focuses on the Chinese consumer, a recent passion project for the central government.

You see, around 2018, when President Xi decided to smother his own economy, notable shifts were already taking place.

The once burgeoning retail market had slowed markedly. Developers left cities abandoned, including weird copies of Paris (Tianducheng) and England.

Source: Shutterstock

So, Xi and co. shifted the focus to the consumer… which went terribly.

For starters, a lot of the consumer wealth was tied up in real estate.

Then you had a growing population of unemployed younger adults who didn’t have any money to spend.

Once the pandemic hit, everything collapsed.

That’s why it took China far longer to recover even a sliver of its former economy.

While it’s not the growth engine of the early 2000s, the old girl still has some life left in it.

As Jim pointed out, China’s consumer spending rebounded nicely in Q4 2023.

Source: National Bureau of Statistics of China

Combined with looser central bank policy, it was only a matter of time before Chinese stocks caught a lift.

The resurgence may be largely tied to China’s desire to travel. After all, its people have been cooped up longer than any other country.

But make no mistake, this doesn’t make China a long-term investment.

Beyond what most people understand about China’s politics, there’s a little-known fact about how they treat foreign investors.

Money in. Nothing out.

When we buy a stock, we’re taking partial ownership in that company. This entitles us to a portion of the profits (or assets).

That doesn’t happen with Chinese companies.

American depository receipts (ADRs) aren’t actual shares of a company. It’s a note that the intermediary ties to shares of the company they own overseas.

So, we can only own Chinese companies indirectly.

But there’s another key feature you probably weren’t aware of.

Many of the Chinese companies we, as Americans invest in, don’t pay dividends. In fact, a much smaller percentage of Chinese companies pay any dividends.

Alibaba is a perfect example.

Despite generating billions of dollars in cash every year, it doesn’t pay dividends.

What do its managers do with the money?

Other than squirreling away $80 billion on its balance sheets, they do share buybacks.

Plenty of investors will tell you that’s even better than dividends.

But you have no legal ownership rights in China. So, what is that ADR in reality?

We’d argue nothing but paper profits at best, and air at worst.

That’s why it’s flat-out dangerous to own shares of individual Chinese companies long-term.

Any one of them can be nationalized at any moment.

Chinese ETFs reduce that risk through diversification, similar to junk bond funds.

Short of an all-out ban, like between the United States and Russia, the majority of the ETF holdings should remain intact.

Opportunistic Investing

If China is so unstable, and capable of changing at a moment’s notice, how can investors uncover pockets of value?

As Jim showed with his ETF selection, you can have some sector or thematic idea so long as you have the data to support it.

China, like any large institution, isn’t going to change its broad economic policies overnight.

As long as you study the general movements of the government, you can steer clear of the catastrophic zones and towards the diamond caves.

Because when things look THIS bad, you know the opportunities are even juicier.

But rather than try to run this maze solo, take this opportunity to check out Jim Woods’ latest report on China.

In it, he details the broad economic themes driving the Chinese government, and how to exploit them for gain.

Click here to explore Jim Woods’ report.

The post TikTok Ban Obscures Chinese Stock Gold Rush appeared first on Stock Investor.

Read More

Continue Reading

International

The Great Escape… of UK Unemployment Reporting

https://bondvigilantes.com/wp-content/uploads/2024/03/1-the-great-escape-of-uk-unemployment-reporting-1024×576.pngThe Bank of England Monetary Policy Committee…

Published

on

https://bondvigilantes.com/wp-content/uploads/2024/03/1-the-great-escape-of-uk-unemployment-reporting-1024x576.png

The Bank of England Monetary Policy Committee potentially has a problem: it requires data to make its labour market forecasts and assessments, but the unemployment statistics have become increasingly unreliable. This is because the Labour Force Survey participation rate (on which the unemployment figures are based) has fallen below 50% since 2018 and has been as low as 15% recently[1]. What is the solution to this difficult measurement problem? An answer can be found in the classic war film, The Great Escape.

In 1943, the Escape Committee of Stalag Luft III was tasked with digging a tunnel to freedom. Unfortunately, they had a problem. They needed to measure the distance between one of the prisoner’s huts and the forest beyond the prison perimeter, but they had no reliable tools to measure this critical variable. Fortunately they had two mathematicians within the group who came up with a method to gauge the distance to the forest so that the tunnel would be long enough to ensure escape without detection. The idea was to eyeball the distance using a 20 foot tree for scale (the tree was the one ‘accurate’ measurement around which they could work with). They got individual prisoners to gauge the distance from the hut to the tree and then averaged all of the estimates. The critical distance measure was therefore the average of a large sample size of guesstimates. Fortunately, it more or less worked. Happily, modern economists have an equivalent to rely on in the area of unemployment. Their version of the Stalag Luft III tree strategy is something called the Beveridge Curve.

The Beveridge Curve is simply an observed relationship between an economy’s unemployment rate and its job vacancy rate at the same point in time. An excellent exposition can be found in the Bond Vigilantes archive[2]. When you plot the two variables against one another over a given period, the data points disclose a curve. This curve shows us that when unemployment increases, job vacancies decrease and vice versa. I have plotted the current curve below using the available data from the Office for National Statistics (ONS)[3]. The bottom left quadrant of the graph (the blue dots) relate to the Covid-19 era and the top left quadrant (the purple dots) represent the last 2 years’ worth of data. The green dots represent the remaining data from July 2004 to June 2023.


Source: Office for National Statistics, Dataset JP9Z & UNEM


Source: Office for National Statistics, Dataset JP9Z & UNEM

From these charts and new data from the ONS, we can observe that in the UK, the level of unemployment is increasing and that the job vacancy rate is decreasing. At face value, this suggests that current Bank of England monetary policy is working and that the inflation rate is slowing as the economy cools. One could argue that we are on track for a reasonably soft landing. Nothing new so far.

Things become more interesting when we consider the Beveridge Curve in conjunction with the most recent job vacancy data. We are told that there are now 814,000 job vacancies as of the 31st December 2023[4]. Ordinarily, we would use the curve and clearly be able to extrapolate from the Job Vacancy data what our Unemployment figure might be. However, we also know that the current unemployment data is unreliable, which makes this harder. Using our model inclusive of data oddities, we could extrapolate that with 814,000 job vacancies, we might expect an unemployment rate of around 3.5%. Yet, we know that our unemployment figures are unreliable so the question therefore is, how big an increase in unemployment are we likely to see given what we know about job vacancies?

In order to estimate the magnitude of the rise in unemployment, we need to look further afield. If we study the levels of economic inactivity in the UK, we can observe that they have remained stationary at 22%[5] for the last decade. We can also see that the population of the UK has risen over the same period by around 5.91%[6]. Further, we know that the Labour Force Survey (LFS) samples 40,000 households per quarter to obtain its data, but of late has had a response rate of only 15% (6,000 households). Therefore a critical question for policy makers is what is happening with the 85%, the non-responders?

Given the small sample size, it is entirely possible that the LFS suffered survey bias that is being erroneously weighted away. In other words, the LFS compensates for the paucity of response data by accessing other regional population statistics as a legitimate part of their methodology. The problems of non-responders are being addressed in upcoming LFS releases but for the time being, the data is not as clear as it ought to be. With such a small sample size, it seems possible – indeed probable –  that unemployment levels are being underreported. This would explain why the current unemployment rate of 3.8%[7] is dramatically lower than the historic average of 6.7% (1971-2023). We see further evidence for this in the forecasts of the UK’s unemployment rate on Bloomberg which have been consistently above the actual levels for the last few published data points. So whilst the published headline figures might be looking reasonable, the underlying story looks like it could be hiding something more sinister.

Through it all, the Beveridge Curve remains a reasonable template. Job vacancies are definitely falling, so we should expect to see unemployment rising. Like the Stalag Luft III measurement solution, the Beveridge Curve offers a constructive way out of our present statistical dilemma. That being said, analogies can only be taken so far. Unfortunately for the inmates of Stalag Luft III, the calculation didn’t quite work and the tunnel came up short. No one actually made a Great Escape. What does this mean for UK unemployment data? Time may tell.

[1] The UK’s ‘official’ labour data is becoming a nonsense (harvard.edu)

[2] https://bondvigilantes.com/blog/2013/11/a-shifting-beveridge-curve-does-the-us-have-a-long-term-structural-unemployment-problem/

[3] Unemployment – Office for National Statistics (ons.gov.uk)

[4] https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/timeseries/jp9z/unem

[5] https://www.ethnicity-facts-figures.service.gov.uk/work-pay-and-benefits/unemployment-and-economic-inactivity/economic-inactivity/latest/#:~:text=data%20shows%20that%3A-,22%25%20of%20working%20age%20people%20in%20England%2C%20Scotland%20and%20Wales,for%20a%20job)%20in%202022

[6] https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2021

[7] https://www.ons.gov.uk/employmentandlabourmarket/peoplenotinwork/unemployment

Read More

Continue Reading

International

Germany Is Running Out Of Money And Debt Levels Are Exploding, Finance Minister Warns

Germany Is Running Out Of Money And Debt Levels Are Exploding, Finance Minister Warns

By John Cody of Remix News

German Finance Minister…

Published

on

Germany Is Running Out Of Money And Debt Levels Are Exploding, Finance Minister Warns

By John Cody of Remix News

German Finance Minister Christian Lindner is warning his own government that state finances are quickly growing out of hand, and the government needs to change course and implement austerity measures. However, the dispute over spending is only expected to escalate, with budget shortfalls causing open clashes among the three-way left-liberal coalition running the country.

With negotiations kicking off for the 2025 budget, much is at stake. However, the picture has been complicated after the country’s top court ruled that the government could not shift €60 billion in money earmarked for the coronavirus crisis to other areas of the budget, with the court noting that the move was unconstitutional.

Since then, the government has been in crisis mode, and sought to cut the budget in a number of areas, including against the country’s farmers. Those cuts already sparked mass protests, showcasing how delicate the situation remains for the government.

German Finance Minister Christian Lindner attends the cabinet meeting of the German government at the chancellery in Berlin, Germany. (AP Photo/Markus Schreiber)

Lindner, whose party has taken a beating in the polls, is desperate to create some distance from his coalition partners and save his party from electoral disaster. The finance minster says the financial picture facing Germany is dire, and that the budget shortfall will only grow in the coming years if measures are not taken to rein in spending.

“In an unfavorable scenario, the increasing financing deficits lead to an increase in debt in relation to economic output to around 345 percent in the long term,” reads the Sustainability Report released by his office. “In a favorable scenario, the rate will rise to around 140 percent of gross domestic product by 2070.”

Under EU law, Germany has limited its debt levels to 60 percent of economic output, which requires dramatic savings. A huge factor is Germany’s rapidly aging population, with a debt explosion on the horizon as more and more citizens head into retirement while tax revenues shrink and the social welfare system grows — in part due to the country’s exploding immigrant population.

Lindner’s partners, the Greens and Social Democrats (SPD), are loath to cut spending further, as this will harm their electoral chances. In fact, Labor Minister Hubertus Heil is pushing for a new pension package that will add billions to the country’s debt, which remarkably, Lindner also supports.

Continue reading at rmx.news

Tyler Durden Mon, 03/18/2024 - 05:00

Read More

Continue Reading

Trending